Key Takeaways
- Age-related macular degeneration (AMD) is the leading cause of blindness after age 50.
- AMD causes progressive loss of central vision while peripheral vision often remains intact.
- Wet AMD can be treated with injections that slow progression but rarely restore vision.
- Dry AMD accounts for about 90% of cases and currently has no approved drug treatment.
- AMD is associated with insulin resistance and cellular senescence, both linked to reduced AMPK activity.
- Metabolic Engineering® aims to increase AMPK activity through diet, omega-3 fatty acids, and polyphenols.
- Early research suggests high-dose omega-3 fatty acids may improve vision in dry AMD patients.
Age-Related Macular Degeneration (AMD) and Metabolism
Age-related macular degeneration (AMD) is the leading cause of vision loss in adults over age 50. While most treatments focus on slowing disease progression, emerging metabolic research suggests that underlying factors such as insulin resistance, inflammation, and cellular aging may also influence retinal health.
Metabolic Engineering®, developed by Dr. Barry Sears, focuses on improving metabolic function by activating AMPK, a master regulator of cellular metabolism that helps reduce inflammation and oxidative stress.
The Problem: Age-Related Macular Degeneration
The most common ocular disease associated with aging is age-related macular degeneration (AMD).
AMD affects the macula, the central part of the retina responsible for sharp, detailed vision. As the disease progresses, individuals gradually lose their central vision, making it difficult to read, recognize faces, or see fine details at any distance.
Peripheral vision typically remains intact, but severe central vision loss can eventually lead to legal blindness.
AMD is currently the primary cause of blindness in adults over age 50.
The Traditional Medical Approach
There are two primary forms of AMD:
Wet AMD
Wet AMD accounts for approximately 10% of cases. It is characterized by abnormal blood vessel growth in the retina.
Treatment typically involves monthly injections of monoclonal antibodies into the eye, which can slow the progression of the disease. However:
- Vision rarely improves significantly.
- Treatments must be continued indefinitely.
- When injections stop, the disease usually continues progressing toward vision loss.
Dry AMD
Dry AMD represents about 90% of cases.
Unlike wet AMD, there is currently no approved drug treatment to halt or reverse the progression of dry AMD.
The Metabolic Engineering® Approach
Research suggests that AMD is strongly associated with two metabolic factors:
- Insulin resistance
- Cellular senescence (aging cells)
Both conditions are linked to reduced activity of AMPK, a key enzyme that regulates metabolism and cellular repair processes (1, 2).
The goal of Metabolic Engineering® is to increase AMPK activity throughout the body—including the retina—by using targeted dietary strategies.
The program combines three core nutritional components:
1. The Zone Diet
The dietary foundation of Metabolic Engineering® is the Zone Diet, which restricts calories without causing hunger or fatigue. This dietary balance helps increase AMPK activity and improve metabolic efficiency.
2. Omega-3 Fatty Acids
Omega-3 fatty acids help:
- Reduce inflammation
- Promote the resolution of inflammatory responses
- Indirectly activate AMPK
3. Polyphenols
Polyphenols are plant-based antioxidants that help reduce oxidative stress, another contributor to retinal aging. Polyphenols also indirectly stimulate AMPK activity.
Together, these three components form a dietary strategy designed to maximize AMPK activity, which may help improve metabolic health in retinal tissue.
Research on Omega-3 Fatty Acids and AMD
A preliminary clinical trial found that high-dose omega-3 fatty acid supplementation significantly improved vision in patients with dry AMD (3).
These findings suggest that increasing omega-3 intake may help improve retinal metabolism by:
- Reducing insulin resistance
- Reducing cellular senescence
- Increasing AMPK activity in retinal cells
Although further research is needed, this evidence indicates that metabolic interventions may play an important role in supporting retinal health.
References
1. Roddy GW.Metabolic syndrome and the aging retina. Curr Opin Ophthalmol. 2021; 32: 280-287. doi: 10.1097/ICU.0000000000000747.
2. Lee KS, Lin S, Copland DA, Dick AD, Liu J.Cellular senescence in the aging retina and developments of senotherapies for age-related macular degeneration.J Neuroinflammation. 2021; 18: 32. doi: 10.1186/s12974-021-02088-0.
3. Georgiou T, Neokleous A, Nicolaou D, Sears B.Pilot study for treating dry age-related macular degeneration (AMD) with high-dose omega-3 fatty acids, PharmaNutrition 2014 2:8-11. doi.org/10.1016/j.phanu.2013.10.001.
For more Ocular Disease content, click here
